26 research outputs found
Efficient Estimation of the Equilibrium Solution-Phase Fugacity of Soluble Nonelectrolyte Solids in Binary Solvents by Molecular Simulation
We
present an efficient means to estimate the concentration-dependent
solution-phase fugacity of soluble nonelectrolyte solids in binary
solvents by molecular simulation. The underlying assumption of the
proposed method is that the solute does not associate or interact
with other solute molecules in solution. Solute–solvent and
solvent–solvent interactions are taken into account by calculation
of the solute solution-phase fugacity at infinite dilution by molecular
simulation, and the concentration dependence of the fugacity is taken
into account analytically by a combinatorial activity coefficient
model. The required simulation data can be computed using any conventional
free energy calculation methodology available in many open-source
simulation software packages. Moreover, with knowledge of the fugacity
of the solid phase, the equilibrium solubility can be calculated.
The method has advantages over empirical descriptor-based methods
in that the molecular simulations enable insight into the underlying
driving forces of the process and do not require extensive parametrization
against experimental data. Results are presented for acetaminophen
in binary aqueous solvents of water/acetone and water/2-propanol.
For both solvent systems, we compare five solute force fields, giving
insight into force field selection to yield accurate predictions.
Also, predictions are made using the UNIFAC group-contribution method
and the state-of-the-art 2005 revised MOSCED model, demonstrating
that the accuracy of molecular simulation can be comparable to that
of conventional methods for predictive purposes
Efficient Estimation of the Equilibrium Solution-Phase Fugacity of Soluble Nonelectrolyte Solids in Binary Solvents by Molecular Simulation
We
present an efficient means to estimate the concentration-dependent
solution-phase fugacity of soluble nonelectrolyte solids in binary
solvents by molecular simulation. The underlying assumption of the
proposed method is that the solute does not associate or interact
with other solute molecules in solution. Solute–solvent and
solvent–solvent interactions are taken into account by calculation
of the solute solution-phase fugacity at infinite dilution by molecular
simulation, and the concentration dependence of the fugacity is taken
into account analytically by a combinatorial activity coefficient
model. The required simulation data can be computed using any conventional
free energy calculation methodology available in many open-source
simulation software packages. Moreover, with knowledge of the fugacity
of the solid phase, the equilibrium solubility can be calculated.
The method has advantages over empirical descriptor-based methods
in that the molecular simulations enable insight into the underlying
driving forces of the process and do not require extensive parametrization
against experimental data. Results are presented for acetaminophen
in binary aqueous solvents of water/acetone and water/2-propanol.
For both solvent systems, we compare five solute force fields, giving
insight into force field selection to yield accurate predictions.
Also, predictions are made using the UNIFAC group-contribution method
and the state-of-the-art 2005 revised MOSCED model, demonstrating
that the accuracy of molecular simulation can be comparable to that
of conventional methods for predictive purposes
HFC-32 and HFC-125 adsorption in the zeolite silicalite
This project contains the raw data obtained from experiments and grand canonical Monte Carlo simulations of adsorption of HFC-32 and HFC-125 in the zeolite silicalite
Identification and treatment of offenders with attention-deficit/hyperactivity disorder in the prison population: a practical approach based upon expert consensus
Abstract Background Around 25% of prisoners meet diagnostic criteria for attention-deficit/hyperactivity disorder (ADHD). Because ADHD is associated with increased recidivism and other functional and behavioural problems, appropriate diagnosis and treatment can be a critical intervention to improve outcomes. While ADHD is a treatable condition, best managed by a combination of medication and psychological treatments, among individuals in the criminal justice system ADHD remains both mis- and under-diagnosed and consequently inadequately treated. We aimed to identify barriers within the prison system that prevent appropriate intervention, and provide a practical approach to identify and treat incarcerated offenders with ADHD. Methods The United Kingdom ADHD Partnership hosted a consensus meeting to discuss practical interventions for youth (< 18 years) and adult (≥18 years) offenders with ADHD. Experts at the meeting addressed prisoners’ needs for effective identification, treatment, and multiagency liaison, and considered the requirement of different approaches based on age or gender. Results The authors developed a consensus statement that offers practical advice to anyone working with prison populations. We identified specific barriers within the prison and criminal justice system such as the lack of adequate: staff and offender awareness of ADHD symptoms and treatments; trained mental health staff; use of appropriate screening and diagnostic tools; appropriate multimodal interventions; care management; supportive services; multiagency liaison; and preparation for prison release. Through discussion, a consensus was reached regarding prisoners’ needs, effective identification, treatment and multiagency liaison and considered how this may differ for age and gender. Conclusions This practical approach based upon expert consensus will inform effective identification and treatment of offenders with ADHD. Appropriate intervention is expected to have a positive impact on the offender and society and lead to increased productivity, decreased resource utilization, and most importantly reduced rates of re-offending. Research is still needed, however, to identify optimal clinical operating models and to monitor their implementation and measure their success. Furthermore, government support will likely be required to effect change in criminal justice and mental health service policies
Supplementary Figure 6 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors
Supplementary Figure 6:Â Synergy quantitation for CB307 / pembrolizumab combination</p
Supplementary Video 1 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors
Supplementary Video 1</p
Supplementary Table 1 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors
Supplementary Table 1: Mouse PK summary statistics</p